A perspective on potential antibody-dependent enhancement of SARS-CoV-2
Ann M. ArvinStanford University School of Medicine, Stanford, CA, USA. [email protected]Katja FinkHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, SwitzerlandMichael SchmidHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, SwitzerlandAndrea L. CathcartVir Biotechnology, San Francisco, CA, USARoberto SpreaficoVir Biotechnology, San Francisco, CA, USAColin Havenar‐DaughtonVir Biotechnology, San Francisco, CA, USAAntonio LanzavecchiaHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, SwitzerlandDavide CortiHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, SwitzerlandHerbert W. VirginVir Biotechnology, San Francisco, CA, USA. [email protected]
2020en
ABI
Аннотация
Аннотация отсутствует.
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0